[Adjuvant chemotherapy of malignant bone tumors].
The interdisciplinary approach in the combined modality treatment of non-metastasized osteogenic sarcoma follows now well-established guidelines: (1) diagnostic biopsy; (2) pretherapeutic cytostatic polychemotherapy (cyclic administration of adriamycin, high-dose methotrexate or cis-platinum, BCD = bleomycin + cyclophosphamide + dactinomycin); (3) limb-saving oncological radical operation with histological evaluation of the effectiveness of the preoperative chemotherapy; (4) continuation of the preoperative chemotherapy as postoperative adjuvant chemotherapy. This interdisciplinary approach in the treatment of localized osteogenic sarcoma has improved the 5-year survival rate from 20% to 80%.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy*
D000970:Antineoplastic Agents
Adjuvante Chemotherapie bei malignen Knochentumoren.